人表皮生长因子受体3（human epidermal growth factor receptor 3，Her3）是人表皮生长因子跨膜受体家族的成员。Her3可通过配体依赖和非依赖的二聚化激活，进而激活下游关键的信号通路，如磷脂酰肌醇3激酶-丝氨酸苏氨酸蛋白激酶信号通路和丝裂原活化蛋白激酶信号通路，参与肿瘤的病理进程及肿瘤对靶向药物治疗、化疗等的耐受。目前，Her3已经成为乳腺癌、卵巢癌等肿瘤治疗极具前景的候选靶点。此文综述了Her3与肿瘤对靶向治疗等耐受的关系及靶向Her3单克隆抗体药物开发的研究进展。

 Human epidermal growth factor receptor 3 (Her3) is a member of human epidermal growth factor receptor family. It can be activated by ligand-dependent or -independent dimerization, then regulates downstream key signaling pathways, such as phosphatidylinositol 3-kinase-serine/threonine kinase pathway or mitogen-activated protein kinase pathway. Hence, it is involved in tumor pathogenesis and tumor tolerance to targed drug therapy and chemotherapy. Her3 has become a promising new target for treatment of breast cancer, ovary caner, etc. This paper reviews the research progress in the relation between Her3 and tumor tolerance to targeting drug therapy, and also introduces new progress in development of monoclonal antibodies targeting Her3.